Had $10m net assets (last 10Q, mostly cash on hand) just funded for more $26.8m. vs $20m MC.
the Chairman, invested $1.7M recently. way undervalued relating Equity and Market Potential (As described in yesterday's Letter to Shareholders).very recommended at current price.
Pipeline in Progressive Stages
Phase 3
• Lead product (Mino-Lok) is a unique antibiotic lock therapy that salvages central lines in bacteremic patients, has been granted QIDP, and is in Phase 3. There is no approved competition nor any on the horizon. We estimate the market to be >$1 billion worldwide.
Phase 2
• Gastrointestinal product (topical hemorrhoid symptomatic treatment) Phase 2a completed with positive directional results showing improvement over components and vehicle. This product would be the only FDA approved Rx therapy for hemorrhoids. Market is >4 million Rxs and we estimate the dollar market to be >$1 billion in US.
ü Targeted Acquisitions
• Business development activity focused on adjunctive cancer care (infection, chronic pain, nausea, etc.). Fast growing segment with exceptional opportunities.
My posts are my opinion and should not be used as investment advice. Make your own decisions in your stock trades.
Recent CTXR News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2024 12:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/11/2024 09:26:01 PM
- Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference • PR Newswire (US) • 09/05/2024 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/05/2024 08:15:10 PM
- Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology • PR Newswire (US) • 09/05/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 08:01:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 08:01:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2024 08:35:55 PM
- Form SC 13D - General Statement of Acquisition of Beneficial Ownership • Edgar (US Regulatory) • 08/16/2024 08:34:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 10:25:24 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 10:19:43 PM
- Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update • PR Newswire (US) • 08/12/2024 09:28:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 09:25:09 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/12/2024 09:10:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/12/2024 08:51:13 PM
- Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc. • PR Newswire (US) • 08/12/2024 08:22:00 PM
- Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments • PR Newswire (US) • 08/12/2024 12:00:00 PM
- TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update • GlobeNewswire Inc. • 08/09/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 01:20:18 PM
- Citius Pharmaceuticals Receives FDA Approval for LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma • PR Newswire (US) • 08/08/2024 10:59:00 AM
- Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc. • PR Newswire (US) • 08/05/2024 12:00:00 PM
- TenX Keane Acquisition Shareholders Approve Previously Announced Merger to Form Citius Oncology, Inc., a Publicly Listed Subsidiary of Citius Pharmaceuticals • GlobeNewswire Inc. • 08/05/2024 12:00:00 PM
- Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates • PR Newswire (US) • 07/10/2024 01:10:00 PM
- Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution • PR Newswire (US) • 05/29/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2024 08:05:34 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM